Neumora Therapeutics, Inc. (NMRA)
NASDAQ: NMRA · Real-Time Price · USD
1.400
+0.020 (1.45%)
Mar 13, 2025, 4:00 PM EDT - Market closed
Neumora Therapeutics Stock Forecast
NMRA's stock price has decreased by -91.84% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Neumora Therapeutics stock have an average target of 10.14, with a low estimate of 2.00 and a high estimate of 20. The average target predicts an increase of 624.29% from the current stock price of 1.40.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Neumora Therapeutics stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Buy | 3 | 2 | 2 | 2 | 2 | 1 |
| Hold | 0 | 1 | 1 | 1 | 1 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 6 | 6 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Mar 10, 2025 |
| Stifel | Stifel | Strong Buy → Hold Downgrades $6 → $2 | Strong Buy → Hold | Downgrades | $6 → $2 | +42.86% | Mar 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +1,185.71% | Mar 7, 2025 |
| RBC Capital | RBC Capital | Hold Reiterates $4 | Hold | Reiterates | $4 | +185.71% | Mar 4, 2025 |
| Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +257.14% | Mar 4, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
22.50M
EPS This Year
-1.65
from -1.53
EPS Next Year
-1.62
from -1.65
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 82.3M | 247.0M | ||
| Avg | n/a | 22.5M | 176.1M | ||
| Low | n/a | n/a | 21.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 997.5% | ||
| Avg | - | - | 682.8% | ||
| Low | - | - | -2.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.17 | -0.68 | -0.67 | ||
| Avg | -1.65 | -1.62 | -1.12 | ||
| Low | -1.90 | -2.06 | -1.34 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.